Your reps talk to clinics all day. Every sentence they say about an HCT/P, a PRP kit, or an exosome product is a marketing claim. Distributor compliance is the set of rules that keeps those sentences inside the law. Here are nine of them, written for the owner of a distributor or the sales leader at a product company.
TLDR: The product’s status sets the ceiling on what a rep may say. “Registered” never means “approved.” Distributor compliance also means treating every spoken pitch as future ad copy, because the clinic will repeat it. The fix is a written claim sheet, rep training, and a record that both happened. Read on for the nine rules, the mistakes we see most, and a scenario that shows how a pitch becomes a problem.
Important Note
This article is for educational purposes only and does not constitute legal, medical, or regulatory advice. Marketing strategies discussed should be reviewed by qualified legal counsel before implementation, particularly regarding FDA, FTC, and state-specific advertising regulations. Regen Portal is a marketing and consulting company, not a law firm. Nothing here implies FDA approval of any product or any use. Most cell, tissue and exosome products marketed to patients are not FDA approved, and the few cell-based products the FDA has approved are approved only for specific labeled indications. Nothing here promises a marketing or business outcome. Regulations change and enforcement varies by state. Confirm current requirements with qualified legal and compliance counsel before you act on anything you read here.
Reps routinely say things to clinic owners that are not FDA compliant. In this industry, that is treated as normal. We have watched that language travel from the rep’s pitch into the clinic’s own ads and marketing. Sometimes it lands word for word, “best thing since sliced bread” and all, repeated to the clinic’s patients and referral network.
Nobody planned that. The rep was excited. The clinic owner trusted the rep. Six months later the product name sits on a service page next to a claim nobody can back up. This post gives you nine rules that stop the chain at the first link.
Why Distributor Compliance Starts With the Rep
The rep is the first marketer of your product. The clinic treats the rep’s words as the product’s official position. So distributor compliance is a sales management task with legal support, not a legal task alone.
We have worked with dozens of manufacturers and distributors on consulting and marketing, and the pattern repeats. The lab does careful work. The regulatory team writes careful labels. Then the sales team goes out and talks, and nobody wrote down what it may say.
The FTC does not separate those groups. Its guidance says anyone taking part in deceptive marketing may be liable, and it names distributors and retailers alongside marketers, per the FTC health products guidance. The same guidance holds a marketer equally responsible for implied claims. A rep’s hint carries the same weight as a rep’s sentence.
So the first job is to find the ceiling, and that comes from the product itself.
Rules 1 to 3: Product Status Sets the Ceiling
Every sentence a rep says must fit under the product’s regulatory status. No pitch can lift a product above that status. The wrong sentence can pull it below.
Rule 1: the product’s status sets the ceiling on every sentence. For a cell or tissue product, that status usually turns on 21 CFR 1271.10. A product stays under section 361 only if it meets every criterion there, including minimal manipulation and homologous use. The rule judges homologous use by “the labeling, advertising, or other indications of the manufacturer’s objective intent,” per 21 CFR 1271.10. A rep’s pitch is advertising.
A rep who describes a non-homologous use may be describing a product that no longer fits under 361. Counsel decides that question, but the rep opened it. That is why distributor compliance matters more than most sales leaders think.
Rule 2: “registered” and “listed” are not “approved,” and a rep may not use them to imply it. Makers of 361 HCT/Ps must register with the FDA and list each product. The FDA’s own page says acceptance of a registration does not mean the product “is licensed or approved by FDA,” per the tissue establishment registration page. Registration is a filing.
“We are FDA registered,” said in a tone that suggests approval, is misleading. “FDA registered clinic” is the credential claim we see most often on regen sites. Your reps are often where the clinic learned it.
Rule 3: no disease, treatment, or outcome claim for a 361 product. The FDA consumer alert, last updated in April 2024, says most such products are unapproved and no exosome product is approved. The FDA has approved a small number of cell-based products, each only for a specific labeled use. A rep who says “this treats knee arthritis” has made a disease claim for an unapproved product. Saying it out loud does not soften it.
If your team is fuzzy on the line, start with the 361 and 351 distinction before the next ride-along. PRP kits follow the same logic: the clearance names the use, and the clearance is the ceiling.
Once the ceiling is set, the next three rules cover how reps talk under it.
Rules 4 to 6: What a Rep May Say
A rep may describe the product, how it is made, and what the published science shows. A rep may not rank it, promise with it, or dress research up as proof. Rules four through six draw those lines.
Rule 4: no superlatives. “Best,” “most effective,” “most potent,” and “the future of medicine” are all claims. The FTC judges the net impression of the whole message, not the literal words. “Most effective” implies a comparison someone measured. Nobody did. “Doctors love it” is an implied outcome claim wearing a smile.
Rule 5: research framing must say what the research is and is not. A rep may share a published study. A rep may not say “studies prove” when one small study on a different product exists. The FTC guidance is direct: the studies must match the product and the claim. Teach reps to say “we have no clinical data for that use” when that is true. Clinics respect it more than hype. One more limit applies to cell and tissue products. A study or white paper about a use the product is not listed for can be read as proof of what you intend it for. Reps share only what counsel has cleared.
Rule 6: anything the rep says can end up on the clinic’s website and in its ads, so speak as if it will. The clinic will not check the sentence with counsel. It will paste it into a Facebook ad, a service page, and a front desk script. Our guide to what regen clinics can and cannot say is worth handing to your reps. Would you want the sentence under the product name on a billboard?
The table below shows three common rep lines and what each implies. The third column stays under the ceiling.
| What the rep said | What it implies | What to say instead |
|---|---|---|
| “This is the most potent exosome on the market” | A measured comparison | “Here is our certificate of analysis” |
| “Doctors are seeing great results with knees” | An outcome and a disease use | “We have no clinical data for that use. Here is our claim sheet.” |
| “We are FDA registered, so you are covered” | FDA approval or endorsement | “We are registered and listed; here is the listing” |
The rewrites are less exciting, and that is the point.
Rules 7 to 9: Make the Written Version the Only Version
Written materials outrank verbal claims. So the fix for spoken claims is a written claim sheet, training on it, and a record of both. These rules turn distributor compliance from a hope into a system.
Rule 7: the clinic’s marketing exposure can become the supplier’s problem too the day a letter names the product. When an agency writes to a clinic about a claim, the product is usually named in the letter or on the page it cites. Now your product is tied to that claim in a public record.
We do not name companies in our content, even when the action is public. Plenty of clients have changed a page, a deck, or an ad because of a letter; the lesson gets published and the recipient does not. The pattern behind those changes is almost always the same. The clinic repeated what it was told.
Rule 8: written materials outrank verbal claims, so give the clinic a claim sheet. A claim sheet is one page. It lists the product name, its status in plain words, the sentences the clinic may use, and the sentences it may not. It answers “is this FDA approved?” because the clinic will be asked, and our post on handling the FDA question shows why. Counsel reviews the sheet once. Every rep hands it over on the first visit.
Rule 9: train and document. Train reps on the claim sheet before they carry it. Record the date, the attendees, and the version. Retrain when the sheet changes or when a rep joins. If a claim ever comes back, the record shows what the rep was told and when. That record is the difference between a rogue rep and a rogue policy.
Those nine rules are simple to write down and hard to live with, so the same mistakes keep showing up.
Common Distributor Compliance Mistakes
The distributor compliance mistakes we see most are not about bad intent. They come from reps filling a gap the company left open. When a product company hands us a deck, a one-pager, or a website, we flag three things first. Those are non-compliant claims, wording too complex for the buyer, and weak graphics. Claims are almost always first.
The first mistake is letting reps build their own decks. A rep who cannot explain the product in plain words will reach for a superlative. Give them the plain words.
The second is using “registered” as a sales feature. Registration is required for anyone making a 361 HCT/P. It is table stakes, not a badge.
The third is borrowing research from a different product. A study on one cell type, one process, or one dose does not transfer.
The fourth is letting exosome reps talk about disease at all. No exosome product is approved. If your reps sell exosomes, our post on what clinics can still say about them is the closest thing to a script.
The fifth is silence. No claim sheet, no training, no record. Silence looks like consent to a rep and like neglect to an investigator. The next scenario shows where silence leads.
Picture a Rep Whose Pitch Became Ad Copy
Picture a rep who covers pain practices in a mid-sized metro. The rep carries an amniotic product regulated under section 361. On a first visit, the rep calls it the most advanced option in the market and says patients walk out with less pain. The rep leaves a glossy one-pager with the product name and logo.
Two weeks later the practice runs a Facebook ad. The copy says the practice now offers the most advanced regenerative injection available. It says the injection helps patients get back to life without surgery. The product name is in the ad, and the same lines are on a new service page. Nobody at the practice thought of that as a claim. They thought of it as what the rep said.
Now trace the exposure. The ad is a superlative plus an implied outcome claim under the practice’s name. The page is a non-homologous use under the product’s name. Our post on stem cell advertising rules covers why the platform will likely reject the ad. The page is the bigger problem. It ties the product to a use its status does not support, in public.
The fix is not a strong letter to the practice. The fix is the claim sheet that should have been in the rep’s bag on day one. Add a training record that shows the rep was taught to use it. Then rewrite the page with counsel, and send the sheet to every account.
That scenario is generic, and it is also the most common story we hear.
Frequently Asked Questions
What Is Distributor Compliance for Biologics?
Distributor compliance is the set of rules and records that keep every statement about a product inside its regulatory status. It covers spoken pitches, decks, one-pagers, emails, and social posts. A rep’s sentence is a marketing claim, and regulators treat it that way.
Can a Rep Say the Product Is FDA Registered?
A rep may state the fact that the establishment is registered and the product is listed. The rep may not say it in a way that implies approval, clearance, or endorsement. The FDA’s own page says accepting a registration does not mean the product is licensed or approved.
What Can a Rep Say About a 361 Product?
A rep may describe what the product is, how it is sourced and processed, how it is stored, and its listed homologous use. A rep may share published research with honest framing. A rep may not describe a disease use, an outcome, or a comparison to other products. In doubt, point to the claim sheet.
What Belongs on a Claim Sheet?
Five things: the product name, its status in plain words, the approved sentences, the banned sentences, and the honest answer to the FDA approval question. Add the name of the person the clinic may call. Keep it to one page. Version and date it. Counsel signs off once, then it gets updated when the product or the law changes.
How Often Should Reps Be Retrained?
Retrain at every claim sheet change, at every new hire, and at least once a year. Record each session with the date, the attendees, and the sheet version. The record matters as much as the session. It is what you show when a claim comes back.
Does Distributor Compliance Apply to PRP Kits?
Yes. A PRP kit is usually a device with a clearance that names an intended use. The clearance is the ceiling for distributor compliance on that kit. Reps may describe the kit and its cleared use. Uses outside the clearance are a decision for counsel, not a sales script.
Key Takeaways
- The product’s regulatory status sets the ceiling on every sentence a rep says.
- “Registered” and “listed” are filings, not approvals, and reps may not imply otherwise.
- A 361 product carries no disease, treatment, or outcome claim, spoken or written.
- Superlatives and loose research framing are claims you must substantiate.
- Everything a rep says will end up in the clinic’s ads, so hand over a written claim sheet.
- The day a letter names your product, the clinic’s exposure can become yours too.
- Train reps on the claim sheet, record it, and retrain when it changes.
Your Next Step
Distributor compliance is a sales management system, and most product companies have never built one. We help manufacturers and distributors write the claim sheet, review the rep deck, and set up the training record, alongside your counsel. That work sits inside our marketing compliance practice.
Regen Portal sees both sides of this conversation, the supplier and the clinic, which is why the fixes tend to stick.
PS: Send us your rep deck or product one-pager and we will review it for free.
Email: hello@regenportal.com
YouTube: Subscribe to the channel
About Regen Portal
Regen Portal is a marketing and consulting company built for the regenerative medicine industry. We handle practice consulting, marketing compliance, search engine optimization, content creation, social media management, paid advertising, website development, branding, and AI and ops consulting for clinics, manufacturers, distributors, and independent providers. For more on me and how we work, visit Regen Portal and contact us.
About the Author
Oscar Tellez is the founder of Regen Portal, a marketing and consulting company built for the regenerative medicine industry. He has been in this industry since 2015. He started in medical sales and has worked with PRP since 2016. He has reached hundreds of practices and over 200 doctors through sales, teaching and marketing. He holds a B.S. in Exercise Science and Health Promotion from Florida Atlantic University.
